MCID: CLL001
MIFTS: 43

Cellular Schwannoma malady

Categories: Cancer diseases

Aliases & Classifications for Cellular Schwannoma

Aliases & Descriptions for Cellular Schwannoma:

Name: Cellular Schwannoma 12 14 69
Cellular Neurinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3196
NCIt 47 C4724
UMLS 69 C0431124

Summaries for Cellular Schwannoma

Disease Ontology : 12 A neurilemmoma with a predominantly cellular growth but no Verocay bodies.

MalaCards based summary : Cellular Schwannoma, also known as cellular neurinoma, is related to watson syndrome and infiltrating lipoma. An important gene associated with Cellular Schwannoma is NF2 (Neurofibromin 2), and among its related pathways/superpathways are Pathways in cancer and Neuroscience. The drugs Anti-Bacterial Agents and Gentamicins have been mentioned in the context of this disorder. Affiliated tissues include skin, trigeminal ganglion and bone, and related phenotypes are Increased proliferation and behavior/neurological

Related Diseases for Cellular Schwannoma

Diseases related to Cellular Schwannoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
id Related Disease Score Top Affiliating Genes
1 watson syndrome 10.3 NF1 NF2
2 infiltrating lipoma 10.3 S100A1 S100B
3 intrahepatic bile duct cystadenoma 10.3 NF1 S100B
4 pediatric cns embryonal cell carcinoma 10.3 DSP NF2
5 adult central nervous system choriocarcinoma 10.3 S100A1 SLC2A1
6 cervical adenoid cystic carcinoma 10.2 NF1 TP53
7 pineal gland astrocytoma 10.2 NF1 TP53
8 verrucous papilloma 10.2 NF1 NGFR SOX10
9 bronchitis 10.2 NF2 TP53
10 immunodeficiency due to a classical component pathway complement deficiency 10.2 CDKN2A NF2
11 trombiculiasis 10.2 NF1 S100B
12 clear cell adenofibroma 10.2 CDKN2A TP53
13 malt worker's lung 10.2 SLC2A1 TP53
14 porokeratosis 10.2 NF2 S100B TP53
15 lacrimal gland adenoid cystic carcinoma 10.2 CDKN2A TP53
16 pericardium leiomyoma 10.2 CDKN2A TP53
17 central nervous system hemangioma 10.2 NF1 S100B TP53
18 aneurysm of sinus of valsalva 10.2 MDM2 NF2 S100B
19 rommen mueller sybert syndrome 10.1 MDM2 TP53
20 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 10.1 NF2 S100B
21 spondylarthropathy 10.1 CDKN2A TP53
22 t-cell large granular lymphocyte leukemia 10.1 NF1 NF2 TP53
23 diarrhea, chronic, with villous atrophy 10.1 MDM2 NGFR S100B
24 acute mountain sickness 10.1 MDM2 TP53
25 flat ductal epithelial atypia 10.1 CDKN2A NF1 TP53
26 multiple mucosal neuroma 10.1 CD34 DSP
27 mediastinum liposarcoma 10.1 CDKN2A MDM2 S100B
28 glomeruloid hemangioma 10.1 CDKN2A NF1 SOX10
29 cavernous hemangioma of colon 10.1 CD34 NF2
30 enchondromatosis dwarfism deafness 10.1 MDM2 S100B TP53
31 aortic aneurysm 10.1 CDKN2A MDM2
32 intraorbital meningioma 10.1 MDM2 S100A1 TP53
33 nodular cutaneous amyloidosis 10.0 CDKN2A SOX2 TP53
34 c-p angle neurinoma 10.0 NF1 NF2 NGFR S100B SOX10
35 mediastinum angiosarcoma 10.0 MDM2 S100B TP53
36 childhood-onset cerebral x-linked adrenoleukodystrophy 10.0 CDKN2A SOX2 TP53
37 granulomatous myositis 10.0 CDKN2A NF1 NF2 TP53
38 cecum adenoma 10.0 MDM2 S100B TP53
39 adenosarcoma 10.0 MDM2 S100B TP53
40 lacrimal gland squamous cell carcinoma 10.0 CDKN2A TP53
41 demyelinating disease 10.0 CD34 NF2
42 pleuropneumonia 10.0 CD34 CDKN2A
43 arteriosclerosis obliterans 10.0 CD34 TP53
44 endometrial squamous cell carcinoma 10.0 CDKN2A MDM2 TP53
45 cervical verrucous carcinoma 10.0 CDKN2A MDM2 TP53
46 house allergic alveolitis 10.0 CDKN2A MDM2 TP53
47 spinal meninges cancer 10.0 CD34 NF2
48 interstitial lung disease 10.0 CDKN2A MDM2 TP53
49 extraocular retinoblastoma 10.0 CDKN2A MDM2 TP53
50 integumentary system benign neoplasm 10.0 CDKN2A MDM2 TP53

Graphical network of the top 20 diseases related to Cellular Schwannoma:



Diseases related to Cellular Schwannoma

Symptoms & Phenotypes for Cellular Schwannoma

GenomeRNAi Phenotypes related to Cellular Schwannoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 TP53

MGI Mouse Phenotypes related to Cellular Schwannoma:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 NF1 NF2 NGFR S100A1 S100B SLC2A1
2 cellular MP:0005384 10.35 SLC2A1 SOX10 SOX2 SUZ12 TP53 CD34
3 homeostasis/metabolism MP:0005376 10.29 S100B SLC2A1 SOX10 SOX2 TP53 CD34
4 growth/size/body region MP:0005378 10.28 CDKN2A DSP MDM2 NF1 NF2 NGFR
5 embryo MP:0005380 10.25 CDKN2A DSP MDM2 NF1 NF2 SLC2A1
6 integument MP:0010771 10.22 TP53 CD34 CDKN2A DSP MDM2 NF1
7 mortality/aging MP:0010768 10.17 SUZ12 TP53 CDKN2A DSP MDM2 NF1
8 digestive/alimentary MP:0005381 10.16 CDKN2A DSP MDM2 NF1 NGFR SOX10
9 immune system MP:0005387 10.15 CD34 CDKN2A MDM2 NF1 NF2 NGFR
10 craniofacial MP:0005382 10.11 NGFR SOX2 TP53 DSP MDM2 NF1
11 nervous system MP:0003631 10.06 NGFR SLC2A1 SOX10 SOX2 SUZ12 TP53
12 neoplasm MP:0002006 10.02 CD34 CDKN2A MDM2 NF1 NF2 SOX10
13 muscle MP:0005369 10.01 CDKN2A DSP MDM2 NF1 NGFR S100A1
14 liver/biliary system MP:0005370 9.93 CDKN2A MDM2 NF1 NF2 NGFR TP53
15 hearing/vestibular/ear MP:0005377 9.92 NF1 NF2 NGFR SOX2 TP53
16 normal MP:0002873 9.86 MDM2 NF1 NGFR S100A1 S100B SOX10
17 pigmentation MP:0001186 9.7 CDKN2A MDM2 NF1 SOX10 SOX2 SUZ12
18 respiratory system MP:0005388 9.56 CDKN2A NF1 NF2 NGFR S100A1 SOX10
19 skeleton MP:0005390 9.23 CDKN2A MDM2 NF1 NF2 NGFR SOX2

Drugs & Therapeutics for Cellular Schwannoma

Drugs for Cellular Schwannoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
2 Gentamicins Phase 4
3 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Early Phase 1
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
6
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
7
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
8
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
9 Alkylating Agents Phase 3,Phase 2,Phase 1
10 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
11 Protein Kinase Inhibitors Phase 2, Phase 3,Early Phase 1
12 Isophosphamide mustard Phase 3,Phase 2
13 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
14 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
15 Imatinib Mesylate Phase 2, Phase 3 123596
16
Etoposide Approved Phase 2 33419-42-0 36462
17
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
18
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
19
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
20
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
21
Lenograstim Approved Phase 2 135968-09-1
22
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
23
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
24
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492
25
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
26
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
27
Pembrolizumab Approved Phase 2 1374853-91-4
28
nivolumab Approved Phase 2 946414-94-4
29
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
30
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
31
Xylometazoline Approved Phase 1, Phase 2 526-36-3 5709
32
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
33
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
34
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
36
Lapatinib Approved March 2007, Investigational Phase 2,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
37
Docetaxel Approved May 1996, Investigational Phase 1, Phase 2 114977-28-5 148124 9877265
38
Lactitol Phase 2 585-86-4 3871
39
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
40 Endostatins Phase 2 71581480
41 Adjuvants, Immunologic Phase 2
42 Nicotinic Acids Phase 2
43 Trace Elements Phase 2
44 Angiogenesis Inhibitors Phase 2,Phase 1
45 Angiogenesis Modulating Agents Phase 2,Phase 1
46 Vitamin B Complex Phase 2
47 Vitamins Phase 2
48 Etoposide phosphate Phase 2
49 Immunoglobulins Phase 2,Phase 1
50 Antibodies, Monoclonal Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 84)
id Name Status NCT ID Phase
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4
3 Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors Enrolling by invitation NCT02884154 Phase 4
4 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
5 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
6 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
7 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
8 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
9 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3
10 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
11 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2
12 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2
13 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2
14 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
15 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2
16 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2
17 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
18 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2
19 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2
20 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
21 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Recruiting NCT01345136 Phase 2
22 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2
23 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
24 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2
25 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2
26 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
27 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2
28 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2
29 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2
30 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Recruiting NCT02831257 Phase 2
31 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2
32 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2
33 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
34 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2
35 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
36 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2
37 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2
38 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Active, not recruiting NCT02008877 Phase 1, Phase 2
39 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT01661283 Phase 2
40 Study of Aspirin in Patients With Vestibular Schwannoma Not yet recruiting NCT03079999 Phase 2
41 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT02986919 Phase 2
42 PTC299 for Treatment of Neurofibromatosis Type 2 Suspended NCT00911248 Phase 2
43 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2
44 Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2
45 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2
46 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1
47 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1
48 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Completed NCT00030043 Phase 1
49 Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Recruiting NCT03009201 Phase 1
50 Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery Recruiting NCT02700230 Phase 1

Search NIH Clinical Center for Cellular Schwannoma

Genetic Tests for Cellular Schwannoma

Anatomical Context for Cellular Schwannoma

MalaCards organs/tissues related to Cellular Schwannoma:

39
Skin, Trigeminal Ganglion, Bone

Publications for Cellular Schwannoma

Articles related to Cellular Schwannoma:

(show top 50) (show all 61)
id Title Authors Year
1
Cellular schwannoma arising from the gastric wall misdiagnosed as a gastric stromal tumor: A case report. ( 24396458 )
2014
2
Spontaneous acute hemorrhage of intraspinal canal cellular schwannoma with paraplegia: A case report. ( 25488387 )
2014
3
Primary pleural hybrid cellular schwannoma/perineurioma: a case report. ( 24998375 )
2014
4
A recurrent cellular schwannoma. ( 25346907 )
2014
5
Atypical presentation of sinonasal cellular schwannoma: a nonsolitary mass with osseous, orbital, and intracranial invasion. ( 25083375 )
2014
6
Infantile cellular schwannoma developing on the skin with atypical clinical features. ( 25232315 )
2014
7
An unusual location for cellular schwannoma. ( 24718004 )
2014
8
Cellular schwannoma of the retroperitoneum with cystic degeneration, mimicking an ovarian cyst, with CKAE1/AE3 and desmin expression. ( 25180931 )
2014
9
Cellular schwannoma masquerading as malignant peripheral nerve sheath tumour: a diagnostic dilemma. ( 23709140 )
2013
10
Cellular schwannoma arising from sigmoid mesocolon presenting as torsion. ( 24349845 )
2013
11
A spinal epidural dumbbell cellular schwannoma in an infant. ( 22325076 )
2012
12
Low-back pain as the presenting sign in a patient with a giant, sacral cellular schwannoma: 10-year follow-up. ( 21214314 )
2011
13
Meningothelial-like whorls in a retroperitoneal cellular schwannoma: potential diagnostic pitfall. ( 20055955 )
2010
14
Trisomy 17 in congenital plexiform (multinodular) cellular schwannoma. ( 21156251 )
2010
15
Intrapulmonary cellular schwannoma. ( 20868846 )
2010
16
Non-healing ulcer on the great toe due to cellular schwannoma. ( 20055863 )
2009
17
Cellular schwannoma of the abducens nerve: case report and review of the literature. ( 19200646 )
2009
18
A huge cystic cellular schwannoma of the intercostal nerve presenting with dyspnea. ( 19324168 )
2009
19
Cellular schwannoma of the greater superficial petrosal nerve presenting with abducens nerve palsy and xerophthalmia: case report. ( 18981849 )
2008
20
Colocalized cellular schwannoma and plexiform neurofibroma in the absence of neurofibromatosis. Case report. ( 17695403 )
2007
21
A rare case of cellular schwannoma in the pharynx. ( 18306575 )
2007
22
Unusually large cellular schwannoma of the foot. ( 15778474 )
2005
23
Intrasellar and parasellar cellular schwannoma. ( 15185261 )
2004
24
Clonal chromosome abnormalities in a plexiform cellular schwannoma. ( 15041228 )
2004
25
Small juxtadrenal cellular schwannoma. ( 14634806 )
2004
26
Retrobulbar cellular schwannoma. Two cases report and review of the literature. ( 12812319 )
2003
27
Cellular schwannoma: a rare spinal benign nerve-sheath tumor with a pseudosarcomatous appearance: case report. ( 14762614 )
2003
28
A rare case of cellular schwannoma involving the trigeminal ganglion. ( 14756445 )
2003
29
Congenital and childhood plexiform (multinodular) cellular schwannoma: a troublesome mimic of malignant peripheral nerve sheath tumor. ( 14508393 )
2003
30
Cellular schwannoma: report of a case diagnosed intraoperatively with the aid of cytologic imprints. ( 12889049 )
2003
31
A case of cellular schwannoma of the skin presenting as a large ulcerated tumor on the ankle. ( 11837571 )
2002
32
Cellular schwannoma in the oral mucosa. ( 12126009 )
2002
33
Cellular schwannoma: a rare presacral tumour. ( 11939658 )
2002
34
Cellular schwannoma of the posterior fossa. ( 11971068 )
2002
35
Cellular schwannoma of the paranasal sinuses: initial report of a case. ( 11987747 )
2002
36
Giant intrasacral cellular schwannoma treated with high sacral amputation. ( 11413442 )
2001
37
Cellular schwannoma: a benign neoplasm sometimes overdiagnosed as sarcoma. ( 11465777 )
2001
38
Cellular schwannoma of the mandible: a case report. ( 11429752 )
2001
39
Solitary cellular schwannoma (neurilemmoma) showing malignant changes: evaluation through magnetic resonance imaging (M.R.I.), surgical intervention, and histopathology. ( 10209928 )
1999
40
Cellular schwannoma mimics a sarcoma: an example of a potential pitfall in aspiration cytodiagnosis. ( 10319235 )
1999
41
Solitary cellular schwannoma presenting with haemothorax. ( 10325881 )
1998
42
Retrovesical cellular schwannoma. ( 9117235 )
1997
43
Cellular schwannoma of the bronchus. ( 8837342 )
1996
44
Cellular schwannoma: a clinicopathologic, DNA flow cytometric, and proliferation marker study of 70 patients. ( 8630970 )
1996
45
Cellular schwannoma of the mandible: a case report with ultrastructural and immunohistochemical observations. ( 8600243 )
1996
46
Acoustic cellular schwannoma invading the petrous bone: case report. ( 8837812 )
1996
47
Cellular schwannoma. A clinicopathologic, DNA flow cytometric, and proliferation marker study of 70 patients. ( 7850709 )
1995
48
Cellular schwannoma. ( 7978072 )
1994
49
Spinal malignant nerve-sheath tumor or cellular schwannoma? A striking difference in prognosis. ( 8410221 )
1993
50
Cellular schwannomas of the intracranial and intraspinal compartment: morphological and immunological characteristics compared with classical benign schwannomas. ( 8095064 )
1993

Variations for Cellular Schwannoma

Expression for Cellular Schwannoma

Search GEO for disease gene expression data for Cellular Schwannoma.

Pathways for Cellular Schwannoma

GO Terms for Cellular Schwannoma

Cellular components related to Cellular Schwannoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.93 CDKN2A DSP MDM2 NF1 NF2 NGFR
2 cytoplasm GO:0005737 9.44 CD34 CDKN2A DSP MDM2 NF1 NF2
3 nucleolus GO:0005730 9.43 CDKN2A MDM2 NF1 NF2 SUZ12 TP53

Biological processes related to Cellular Schwannoma according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.89 MDM2 S100A1 SOX2 SUZ12 TP53
2 protein complex assembly GO:0006461 9.65 MDM2 SLC2A1 TP53
3 negative regulation of protein kinase activity GO:0006469 9.61 CDKN2A NF1 NF2
4 cellular response to hypoxia GO:0071456 9.58 MDM2 S100B TP53
5 positive regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902895 9.52 NGFR TP53
6 positive regulation of protein export from nucleus GO:0046827 9.51 MDM2 TP53
7 negative regulation of MAPK cascade GO:0043409 9.46 NF1 NF2
8 Ras protein signal transduction GO:0007265 9.43 CDKN2A NF1 TP53
9 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.37 NGFR SOX2
10 positive regulation of apoptotic process GO:0043065 9.35 CDKN2A NF1 NGFR S100B TP53
11 replicative senescence GO:0090399 9.32 CDKN2A TP53
12 cellular response to actinomycin D GO:0072717 9.16 MDM2 TP53
13 negative regulation of cell-matrix adhesion GO:0001953 8.8 CDKN2A NF1 NF2

Molecular functions related to Cellular Schwannoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.8 CDKN2A DSP MDM2 NF1 NF2 NGFR
2 transcription factor binding GO:0008134 9.56 CD34 CDKN2A SOX10 TP53
3 SUMO transferase activity GO:0019789 9.32 CDKN2A MDM2
4 identical protein binding GO:0042802 9.17 MDM2 S100A1 S100B SLC2A1 SOX10 TFG
5 S100 protein binding GO:0044548 9.16 S100A1 S100B

Sources for Cellular Schwannoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....